Synthetic Mini Chromosomes for Antibody Production
Ribbon Biolabs has developed a unique, patented technology for the synthesis of long DNA molecules. As a key product in development through this platform, the company is targeting at the development and production of small, chromo...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto MiChomAbs
Duración del proyecto: 6 meses
Fecha Inicio: 2019-11-13
Fecha Fin: 2020-05-31
Líder del proyecto
RIBBON BIOLABS GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Ribbon Biolabs has developed a unique, patented technology for the synthesis of long DNA molecules. As a key product in development through this platform, the company is targeting at the development and production of small, chromosome-like synthetic modular genetic units - which we term MiChroms - for monoclonal antibody production. The production of therapeutic monoclonal antibodies (mAbs) relies on unstable cell-lines, making the availability of the products limited and very expensive for the end user. Introducing MiChroms to the production process will solve this problem by making production batches larger and lower consumer prices, increasing the affordability of breakthrough medicines to a larger patient population. The MiChroms are tailored to specific cell-lines and specific biopharmaceutical mAbs and are independent modular genetic components that, unlike recombinant engineered master cell-lines, do not interfere with the cell’s functioning. With this approach, we can increase cell-line stability and also cover the market needs. Moreover, the model is scalable because it is bound to reduce production costs, reduce price of the end product and increase supply and product portfolio, benefitting the end user. Our main target market is the development of new biologics, specifically monoclonal antibodies for therapeutics, but will also target biosimilars of the main blockbuster antibodies. We plan to sell our genetic design to companies producing and developing biosimilars, where our roles are: a) the design of the artificial chromosome that is suitable for specific mammalian cell lines (e.g. CHO cells) and b) genetic variants in terms of biopharmaceutical copy-number and post-translational variations. Ribbon Biolabs restricts itself to the production of the mini chromosomes but provides variants as required for the clients to determine the tailored sequence that best fits their lines and processes.